

T-Bird Pharma Inc. Retains Pure for Investor Relations

Victoria, British Columbia, September 30, 2014 – T-Bird Pharma Inc. (TSXV:TPI) (“T-Bird” or the “Company”), a pharmaceutical company focused on developing premium quality medical marijuana products, is pleased to announce that it has retained Pure Advertising & Marketing Inc. (“Pure”) to provide investor relations services on behalf of the Company.

Pure is an established venture capital advisory firm based in Vancouver, BC and has successfully demonstrated the ability to work with junior companies in articulating a company's inherent value to the investment community and strategic partners.

The Agreement is for a term of eighteen months and may be terminated by either party by giving 90 days' written notice of such termination. The Company will pay a monthly retainer fee to Pure of \$7,500 plus HST and any reasonable pre-approved expenses incurred on behalf of the Company. The Company has also granted Kam Thindal, the sole shareholder of Pure, 300,000 incentive options to purchase shares of the Company. The options will follow the guidelines set out in the Company's stock option plan and as set forth by TSX Venture Exchange policy. The investor relations agreement, options and option pricing are subject to the approval of the TSX Venture Exchange.

About Pure

Pure is owned by Mr. Kam Thindal. The firm works with junior public and private emerging companies to provide capital markets advisory and capital raising services in a variety of industries and sectors.

About T-Bird and Thunderbird

Thunderbird Biomedical Inc. is a British Columbia private company incorporated under the BCBCA on January 28, 2013, and is wholly-owned by T-Bird Pharma Inc. The principal activities of Thunderbird are the production of marijuana from its Victoria, British Columbia production facility, as regulated by the *Marihuana for Medical Purposes Regulations (Canada)*. Thunderbird obtained a medical marijuana license to undertake the production of medical marijuana in February 2014, being the fifth company in Canada to obtain such a license. T-Bird is the publically traded parent company of Thunderbird.

ON BEHALF OF THE BOARD

“Robert Gagnon”

CEO and Director

For further information, please contact: Kam Thindal at 604-488-9875.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information

Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”.

We caution you that such “forward-looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.

Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including production and sales of medical marijuana, anticipated revenues, projected size of market, quantities of future medical marijuana production, completion of production facilities and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.

T-Bird Pharma Inc. (the “**Company**”) does not intend, and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, results of production and sale activities, the Company’s historical experience with medical marijuana operations, uninsured risks, regulatory changes, availability of production facilities, timeliness of government approvals and the granting of permits and licenses, changes in prices, actual operating and financial performance of facilities, equipment and processes relative to specifications and expectations. Actual results may differ materially from those expressed or implied by such forward-looking statements.